Lake Street boosts UFP Technologies shares target in light of deal optimism By Investing.com
On Tuesday, Lake Street Capital Markets adjusted its outlook on UFP Technologies (NASDAQ:UFPT) shares, a firm operating within the MedTech sector, by increasing the price target to $344 from the previous $300 while maintaining a Buy rating on the stock. The adjustment comes in response to a recent acquisition made by UFP Technologies, which was well-received by the market.
The new acquisition by UFP Technologies has been highlighted as a strategic fit, meeting several key criteria including its alignment with the MedTech space, its accretive nature to the company’s financial model, and the transaction’s valuation at 1.5 times trailing twelve-month (TTM) revenue and 6.0 times TTM AEBITDA. The deal also enhances UFP Technologies’ relationship with Stryker (NYSE:), a notable player in the industry.
Lake Street Capital Markets expressed confidence in UFP Technologies’ ongoing strategy, noting the company’s active search for additional mergers and acquisitions (M&A) opportunities. Analysts anticipate further announcements that could emerge later in the year, signaling a proactive approach to growth.
The firm’s positive outlook is further supported by expectations of a strong second-quarter performance. Lake Street Capital Markets projects that UFP Technologies is on track to achieve a GAAP Earnings Per Share (EPS) of $9 by 2026 and forecasts the potential to surpass $10 in 2027. The sustained financial growth and strategic acquisitions are key drivers behind the maintained Buy rating and the raised price target.
In other recent news, UFP Technologies has made significant strides with the acquisition of AJR Enterprises for $110 million, a move that aligns with its growth strategy and is expected to enhance its offerings in the medical market. The acquisition has been positively received by the market, ending a two-year period without significant acquisitions by UFP Technologies.
AJR Enterprises, known for its advanced fabric technologies, reported sales of around $75 million for the trailing 12-month period ending March 31, 2024, and an adjusted EBITDA of approximately $18.3 million.
KeyBanc has retained its Sector Weight rating on UFP Technologies following the acquisition, citing valuation reasons. Lake Street Capital Markets has also been observing UFP Technologies closely, raising its price target for the company to $300 while maintaining a Buy rating.
The firm expresses confidence in the company’s ability to exceed conservative consensus estimates, potentially reaching $9 in earnings per share by 2026 and surpassing $10 in 2027.
These recent developments underscore UFP Technologies’ commitment to executing its growth strategy and meeting its financial targets, which include a revenue growth rate of 12%-18%, a gross margin range of 28%-31%, and an operating margin between 15%-18%.
InvestingPro Insights
As UFP Technologies (NASDAQ:UFPT) continues to make waves in the MedTech sector with its recent acquisition, real-time data from InvestingPro shows a robust financial outlook for the company. With a market capitalization of $2.22 billion and a high Price/Earnings (P/E) ratio of 45.42, UFPT is trading at a significant earnings multiple. The company’s P/E ratio has remained steady at 45.5 over the last twelve months as of Q1 2024, reflecting a consistent valuation by the market.
InvestingPro Tips indicate that analysts have revised their earnings upwards for the upcoming period, signaling confidence in UFPT’s financial trajectory. Moreover, the company has experienced significant returns over the last week, with a 1 Week Price Total Return of 11.62%. These metrics underscore the positive sentiment echoed by Lake Street Capital Markets.
For investors interested in a deeper analysis, there are additional InvestingPro Tips available for UFPT, including insights on valuation multiples and profitability forecasts. Those looking to leverage these expert insights can use the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
